^
    1d
    KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma. (PubMed, Mol Ther Oncol)
    Similar findings were observed in metastatic lymph nodes, demonstrating viral activity and tumor suppression. Collectively, these results indicate that KLS-3021 exerts potent anti-tumor efficacy in both primary and metastatic cSCC models, supporting its clinical translation as a multifunctional oncolytic virotherapy targeting the physical and immunological barriers of the tumor microenvironment.
    Journal
    |
    PD-1 (Programmed cell death 1)
    7d
    PuMP: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (clinicaltrials.gov)
    P1, N=51, Recruiting, Duke University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    MVR-C5252
    9d
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | Trial completion date: Jan 2028 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • IMNN-001
    9d
    A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Virogin Biotech Ltd.
    New P2 trial
    |
    VG201
    28d
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Virogin Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    29d
    One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, Immorna Biotherapeutics, Inc. | Phase classification: P1 --> P1/2
    Phase classification
    29d
    Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=19, Completed, Immorna Biotherapeutics, Inc. | Recruiting --> Completed | N=156 --> 19
    Trial completion • Enrollment change
    1m
    CA101-001: A Study of DF6002 Alone and in Combination With Nivolumab (clinicaltrials.gov)
    P1, N=170, Completed, Dragonfly Therapeutics | Recruiting --> Completed | N=438 --> 170 | Trial completion date: Nov 2027 --> Nov 2025 | Trial primary completion date: Jan 2027 --> Nov 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Opdivo (nivolumab) • DF6002
    1m
    A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Beijing Bio-Targeting Therapeutics Technology Co., Ltd
    New P1 trial
    1m
    DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    rocakinogene sifuplasmid (INO-9012)
    2ms
    KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer. (PubMed, Front Oncol)
    Mice were randomized to receive vehicle, docetaxel, or KLS-3021, administered on day 9 (prostate-confined) or day 29 (visible/locally invasive) after implantation of luciferase-labeled PC-3 cells. Mechanistic analyses revealed extracellular matrix degradation, enhanced viral spread, increased immune cell infiltration, M1 macrophage polarization, and features of immunogenic cell death in KLS-3021-treated tumors. These results collectively demonstrate the translational potential of KLS-3021 as a minimally invasive or neoadjuvant therapeutic strategy for prostate cancer, especially in patients for whom early, localized intervention is medically feasible.
    Preclinical • Journal
    |
    PD-1 (Programmed cell death 1) • SPAM1 (Sperm Adhesion Molecule 1)
    |
    docetaxel
    2ms
    Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings. (PubMed, Expert Opin Investig Drugs)
    IMNN-001 gene therapy could add clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. IMNN-001 holds promise for synergistic combinations with immunotherapies requiring intrinsic immune activity.
    Review • Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    IMNN-001